Tag: ImmunityBio

ImmunityBio is making a prominent appearance at the 38th Annual ROTH Conference this week, a move underscored by a remarkable ...

ImmunityBio is advancing the commercial potential of its flagship therapy, ANKTIVA, with a new regulatory submission to the U.S. Food ...

Positive early-stage clinical data for its immunotherapy drug Anktiva, presented by the company's founder, provided a pre-market lift to ImmunityBio ...

A significant update to U.S. cancer treatment protocols has substantially broadened the potential patient population for ImmunityBio's flagship immunotherapy. The ...

A key medical authority has broadened its treatment recommendations for bladder cancer, providing a notable boost for ImmunityBio's commercial prospects. ...

After a multi-month rally, shares of biotechnology firm ImmunityBio are experiencing a notable correction. Investor sentiment has been dampened by ...

ImmunityBio's impressive full-year 2025 results were met with a severe sell-off, highlighting the persistent volatility that continues to characterize this ...

All eyes are on ImmunityBio today as the biotechnology firm prepares to release its full-year 2025 results. This follows the ...

ImmunityBio, a biotechnology firm, has unveiled staggering commercial growth for its cancer therapy ANKTIVA. The company's fiscal 2025 performance was ...

ImmunityBio has achieved a significant regulatory milestone in Europe, securing conditional marketing authorization from the European Commission for its therapy, ...